Clinical Trials Logo

Unresectable Stage III Melanoma clinical trials

View clinical trials related to Unresectable Stage III Melanoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03235245 Active, not recruiting - Stage IV Melanoma Clinical Trials

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

EBIN
Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, 2-arm open-label, randomized comparative phase II study. The objective of this trial is to prospectively evaluate whether a sequential approach with an induction period of 12 weeks with encorafenib + binimetinib followed by combination immunotherapy with nivolumab + ipilimumab improves progression free survival compared to combination immunotherapy nivolumab + ipilimumab alone in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.